{"id":"https://openalex.org/W4378215358","doi":"https://doi.org/10.1158/1078-0432.23183897","title":"Supplementary Figure S5 from Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies","display_name":"Supplementary Figure S5 from Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies","publication_year":2023,"publication_date":"2023-05-25","ids":{"openalex":"https://openalex.org/W4378215358","doi":"https://doi.org/10.1158/1078-0432.23183897"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.23183897","doi":"https://doi.org/10.1158/1078-0432.23183897","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.23183897","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.23183897","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063337705","display_name":"Jason J. Luke","orcid":"https://orcid.org/0000-0002-1182-4908","observed_orcids":["https://orcid.org/0000-0002-1182-4908"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jason J. Luke","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1182-4908","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026538331","display_name":"Sarina Anne Piha-Paul","orcid":"https://orcid.org/0000-0001-9455-1660","observed_orcids":["https://orcid.org/0000-0001-9455-1660"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sarina A. Piha-Paul","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9455-1660","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029723783","display_name":"Theresa Michelle Medina","orcid":"https://orcid.org/0000-0003-0579-4121","observed_orcids":["https://orcid.org/0000-0003-0579-4121"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Theresa Medina","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0579-4121","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089486616","display_name":"Claire F. Verschraegen","orcid":"https://orcid.org/0000-0001-6544-3089","observed_orcids":["https://orcid.org/0000-0001-6544-3089"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Claire F. Verschraegen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6544-3089","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040158883","display_name":"Mary Laura Varterasian","orcid":"https://orcid.org/0009-0007-5921-0984","observed_orcids":["https://orcid.org/0009-0007-5921-0984"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mary Varterasian","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0007-5921-0984","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047910418","display_name":"Aoife M. Brennan","orcid":"https://orcid.org/0000-0002-3413-4723","observed_orcids":["https://orcid.org/0000-0002-3413-4723"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Aoife M. Brennan","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3413-4723","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072429797","display_name":"Richard J. Riese","orcid":"https://orcid.org/0009-0000-3657-6229","observed_orcids":["https://orcid.org/0009-0000-3657-6229"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard J. Riese","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0000-3657-6229","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048162761","display_name":"Anna Sokolovska","orcid":"https://orcid.org/0000-0002-1216-696X","observed_orcids":["https://orcid.org/0000-0002-1216-696X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna Sokolovska","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1216-696X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026638826","display_name":"James Fredric Strauss","orcid":"https://orcid.org/0000-0001-6414-6998","observed_orcids":["https://orcid.org/0000-0001-6414-6998"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James Strauss","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6414-6998","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073805604","display_name":"David L. Hava","orcid":"https://orcid.org/0000-0002-9200-1566","observed_orcids":["https://orcid.org/0000-0002-9200-1566"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David L. Hava","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9200-1566","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5071800834","display_name":"Filip Jank\u00fa","orcid":"https://orcid.org/0000-0002-8123-4065","observed_orcids":["https://orcid.org/0000-0002-8123-4065"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Filip Janku","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8123-4065","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12996","display_name":"Bacterial Cancer Therapy","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/1305","display_name":"Biotechnology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12996","display_name":"Bacterial Cancer Therapy","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/1305","display_name":"Biotechnology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sting-agonist","display_name":"STING agonist","score":0.9950000047683716},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.953000009059906},{"id":"https://openalex.org/keywords/chemokine-signaling","display_name":"chemokine signaling","score":0.9190000295639038},{"id":"https://openalex.org/keywords/cytokine-signaling","display_name":"cytokine signaling","score":1.0},{"id":"https://openalex.org/keywords/tlr-signaling-pathways","display_name":"TLR signaling pathways","score":0.8970000147819519},{"id":"https://openalex.org/keywords/advanced-cancer","display_name":"advanced cancer","score":0.8529999852180481},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.7429999709129333}],"concepts":[{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.8251204490661621},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.6060779690742493},{"id":"https://openalex.org/C2779300339","wikidata":"https://www.wikidata.org/wiki/Q7617409","display_name":"Sting","level":2,"score":0.5210592150688171},{"id":"https://openalex.org/C2778022156","wikidata":"https://www.wikidata.org/wiki/Q576145","display_name":"Strain (injury)","level":2,"score":0.5074376463890076},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.38698264956474304},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3760926425457001},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.30624353885650635},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2744957208633423},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.237007737159729},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.14007261395454407},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.12361150979995728},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1233072578907013},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.11226233839988708},{"id":"https://openalex.org/C97355855","wikidata":"https://www.wikidata.org/wiki/Q11473","display_name":"Thermodynamics","level":1,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.23183897","doi":"https://doi.org/10.1158/1078-0432.23183897","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.23183897","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.23183897.v1","doi":"https://doi.org/10.1158/1078-0432.23183897.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.23183897.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S5_from_Phase_I_Study_of_SYNB1891_an_Engineered_i_E_coli_i_Nissle_Strain_Expressing_STING_Agonist_with_and_without_Atezolizumab_in_Advanced_Malignancies/23183897/1/files/40885010.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/23183897","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figure_S5_from_Phase_I_Study_of_SYNB1891_an_Engineered_i_E_coli_i_Nissle_Strain_Expressing_STING_Agonist_with_and_without_Atezolizumab_in_Advanced_Malignancies/23183897","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.23183897","doi":"https://doi.org/10.1158/1078-0432.23183897","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.23183897","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4378215358.pdf","grobid_xml":"https://content.openalex.org/works/W4378215358.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Supplemental":[0],"Figure":[1],"5.":[2],"Tumor":[3],"biopsy":[4],"gene":[5],"expression":[6],"changes":[7],"in":[8],"chemokine,":[9],"cytokine":[10],"and":[11],"TLR":[12],"related":[13],"signaling":[14],"pathways":[15],"after":[16],"SYNB1891":[17],"treatment.":[18]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-05-26T00:00:00"}